DE68921371D1 - Verfahren zur Herstellung einer an Faktor-VIIa angereicherten Fraktion und ihre Verwendung als Arzneimittel. - Google Patents

Verfahren zur Herstellung einer an Faktor-VIIa angereicherten Fraktion und ihre Verwendung als Arzneimittel.

Info

Publication number
DE68921371D1
DE68921371D1 DE68921371T DE68921371T DE68921371D1 DE 68921371 D1 DE68921371 D1 DE 68921371D1 DE 68921371 T DE68921371 T DE 68921371T DE 68921371 T DE68921371 T DE 68921371T DE 68921371 D1 DE68921371 D1 DE 68921371D1
Authority
DE
Germany
Prior art keywords
medicament
preparation
factor viia
fraction enriched
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921371T
Other languages
English (en)
Other versions
DE68921371T2 (de
Inventor
Jacques Chabbat
Lucette Pejaudier
Marion Steinbuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOND NAT TRANSFUSION SANGUINE
Original Assignee
FOND NAT TRANSFUSION SANGUINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOND NAT TRANSFUSION SANGUINE filed Critical FOND NAT TRANSFUSION SANGUINE
Publication of DE68921371D1 publication Critical patent/DE68921371D1/de
Application granted granted Critical
Publication of DE68921371T2 publication Critical patent/DE68921371T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE68921371T 1988-06-09 1989-06-09 Verfahren zur Herstellung einer an Faktor-VIIa angereicherten Fraktion und ihre Verwendung als Arzneimittel. Expired - Fee Related DE68921371T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8807687A FR2632524B1 (fr) 1988-06-09 1988-06-09 Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament

Publications (2)

Publication Number Publication Date
DE68921371D1 true DE68921371D1 (de) 1995-04-06
DE68921371T2 DE68921371T2 (de) 1996-01-04

Family

ID=9367108

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921371T Expired - Fee Related DE68921371T2 (de) 1988-06-09 1989-06-09 Verfahren zur Herstellung einer an Faktor-VIIa angereicherten Fraktion und ihre Verwendung als Arzneimittel.

Country Status (7)

Country Link
EP (1) EP0346241B1 (de)
JP (1) JPH02504587A (de)
AT (1) ATE119196T1 (de)
DE (1) DE68921371T2 (de)
ES (1) ES2070921T3 (de)
FR (1) FR2632524B1 (de)
WO (1) WO1989012097A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2965069B2 (ja) * 1989-01-13 1999-10-18 吉富製薬株式会社 蛋白質含有組成物の製造方法
FR2684999A1 (fr) * 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2942231B1 (fr) 2009-02-19 2015-03-20 Lfb Biotechnologies Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
FR2946348B1 (fr) * 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
EP2687595B1 (de) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Verfahren zur Reinigung eines transgenen Faktor VII
DK3165232T3 (da) * 2012-12-24 2019-09-16 Coagulant Therapeutics Corp Faktor vii-polypeptider med kortvarig virkning
FR3011250A1 (fr) 2013-09-30 2015-04-03 Lab Francais Du Fractionnement Acides nucleiques se liant specifiquement au facteur ix/ixa humain, et utilisations
RU2559576C1 (ru) * 2014-06-09 2015-08-10 Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ Способ получения вирусбезопасного полного протромбинового комплекса

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4470979A (en) * 1982-09-17 1984-09-11 Janssen Pharmaceutica N.V. Chemical sterilization of insects with salicylanilides
US4473553A (en) * 1983-12-02 1984-09-25 Miles Laboratories, Inc. Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa
US4470969A (en) * 1983-12-02 1984-09-11 Miles Laboratories, Inc. Process for producing a concentrate of coagulation factors VII and VIIa
US4637932A (en) * 1984-10-15 1987-01-20 Miles Laboratories, Inc. Process for producing a concentrate enriched in coagulation factors VII and VIIa

Also Published As

Publication number Publication date
FR2632524B1 (fr) 1992-03-13
FR2632524A1 (fr) 1989-12-15
ATE119196T1 (de) 1995-03-15
WO1989012097A1 (fr) 1989-12-14
EP0346241A1 (de) 1989-12-13
DE68921371T2 (de) 1996-01-04
ES2070921T3 (es) 1995-06-16
EP0346241B1 (de) 1995-03-01
JPH02504587A (ja) 1990-12-27

Similar Documents

Publication Publication Date Title
DE68921371D1 (de) Verfahren zur Herstellung einer an Faktor-VIIa angereicherten Fraktion und ihre Verwendung als Arzneimittel.
KR100261030B1 (en) N-terminally chemically modified protein compositions and methods
IT8441595A0 (it) Composizione per l'embolizzazione dei vasi sanguigni.
DE3887957D1 (de) Mischung zur Absorption von sauren Gasen.
ATE38657T1 (de) Betonzusatz und seine verwendung.
DE3668168D1 (de) Desmosinderivate und reagenz zur herstellung artifizieller antigene.
DE68912160D1 (de) Verfahren zur Herstellung von beta-Lactamderivaten.
NO874210D0 (no) Tilsetning av kalsiumforbindelser til reduksjonssmelting av silisiumdioksid med karbon som reduksjonsmiddel.
DE68924373D1 (de) Verfahren zur Herstellung konzentrierter Granulatkörner von oberflächenaktiven Mitteln.
ATE68601T1 (de) Reagenz zur bestimmung durch haemagglutination von antikoerpern gegen bakterien-toxine, verfahren zu ihrer herstellung und verwendung.
ATE113939T1 (de) Verfahren zur herstellung von cephalosporin und zwischenverbindungen.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
DE58909337D1 (de) Verfahren zur Herstellung von reinen 3-Butenyltriorganyloxysilanen.
DK44184A (da) Deodorant med silaniserede adsorbenter
ES2053704T3 (es) Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales.
GB1480092A (en) Diagnostic agent
IT1178489B (it) Vettore clonante, procedimento per la sua costruzione e procedimento di concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante
DE59408965D1 (de) Verfahren zur Herstellung langzeitstabiler klarer Seren
ATE98215T1 (de) Verfahren zur herstellung von 2-oxo-3aromatischen karbonsaeure-derivaten.
ATE100099T1 (de) Verfahren zur herstellung von zusammensetzungen mit anti-magengeschwuer-wirkung.
DE69314251D1 (de) Verfahren, Coder und Decoder zur Verbesserung der Kompatibilität von HDMAC-Signalen

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee